Clinical and Applied Thrombosis/Hemostasis · 2018 · 22 citations · 15 references
MedicineOncologySurgeryBreast OncologySurgical OncologyVascular SurgeryDeep Vein ThrombosisPulmonary EmbolismThromboembolic DiseaseThrombosisVenous DiseaseVenous ThromboembolismCancer-associated Deep Vein ThrombosisCancer-associated Pulmonary EmbolismCentral Venous Catheter ThrombosisClinical Cancer DiagnosisUpper Extremity Venous ThrombosisVenous Thromboembolism DiagnosisVenous Thromboembolism Epidemiology
Patients with cancer have an increased risk of venous thromboembolism. Upper extremity venous system is a peculiar site, and little is known about the clinical course in patients with cancer. Electronic medical records were searched for patients with cancer with a diagnosis of upper extremity venous thrombosis. Individual patient data were reviewed. Eighty-seven patients were identified, and the median age was 52.4. The most common underlying malignancies were breast (23.0%), colorectal (18.4%), and gastroesophageal (18.4%). Median time from cancer diagnosis to upper extremity venous thromboembolism (UEDVT) was 3.44 months. Subclavian vein was the most common involved site (56.3%) and 54.0% patients had a central venous catheter; 50.6% of patients developed a complication; pulmonary embolism (PE) in 9.2%, superior vena cava (SVC) syndrome in 14.9%, and 26.4% had postthrombotic syndrome. In patients with isolated single vein thrombosis, complications were higher in the subset with internal jugular vein involvement compared to other sites (68.2% vs 52.2%) as were complications in patients with non-catheter-related thrombosis compared to patients with a central venous catheter in place (55% vs 27.7%). Median overall survival from time of cancer and UEDVT diagnoses was 29.6 and 13.25 months, respectively. In conclusion, UEDVT is an uncommon event. Around 50% developed a complication including PE, SVC or postthrombotic syndromes. Larger studies are needed to better identify risks associated with thrombosis and the best therapeutic approach and duration in this unique subset of patients with cancer.
15
Development and validation of a predictive model for chemotherapy-associated thrombosis
Alok A. Khorana, Nicole M. Kuderer, Eva Culakova et al. · Blood · 2008 · 2.2K citations · Full text
Medicine, Hematology, Oncology +14
The Long-Term Clinical Course of Acute Deep Venous Thrombosis
P. Prandoni · Annals of Internal Medicine · 1996 · 2.1K citations
Prognosis of Cancers Associated with Venous Thromboembolism
Henrik Toft Sørensen, Lene Mellemkjær, Jørgen H. Olsen et al. · New England Journal of Medicine · 2000 · 1.6K citations · Full text
Medicine, Hematology, Oncology +12
The Clinical Course of Pulmonary Embolism
Jeffrey L. Carson, Mark A. Kelley, Amy Duff et al. · New England Journal of Medicine · 1992 · 1K citations